4 results about "Dehydroascorbic acid" patented technology

The application belongs to the technical field of nanomaterials, and provides ascorbic acid oxidation mimetic enzyme and preparation thereof. The application adopts a methanol solution of zinc nitrate, copper acetylacetonate and 2-methyl imidazole to perform a hydrothermal reaction, and obtains the ascorbic acid oxidation mimetic enzyme by oxygen isolation calcination of a hydrothermal product. The copper-nitrogen-carbon nanomaterial obtained by the application has a rhombohedron structure, can specifically oxidize ascorbic acid, and can be applied to ascorbic acid content detection, oxidized ascorbic acid preparation and dehydroascorbic acid preparation as ascorbic acid oxidation enzyme mimetic enzyme. The nanomaterial can maintain ascorbic acid oxidation mimetic enzyme activity under acid, alkaline and high temperature conditions; the steady-state kinetic parameter (Michaelis constant is 0.012 mM) is better than that of natural ascorbic acid oxidation enzyme, and the ascorbic acid oxidation mimetic enzyme activity of the material has a broad application prospect in the fields of nanozyme, nanotechnology and biological analysis detection.

The invention discloses environment-friendly copper etching liquid based on a bio-based material and a preparation method of the environment-friendly copper etching liquid. The etching liquid comprises the following components in percentage by weight: 5-20% of a bio-based chelating agent, 3-15% of a bio-based oxidizing agent, 0.5-5% of a pH regulator, 0.1-2% of a corrosion inhibitor, 0.05-1% of a surfactant and the balance of deionized water, the bio-based chelating agent is selected from citric acid, glutamic acid and the like and salts thereof; the bio-based oxidant is selected from dehydroascorbic acid, phytic acid and the like. The preparation method comprises the following steps: sequentially dissolving the chelating agent, adjusting the pH value to 3.0-7.0, adding the oxidizing agent, the corrosion inhibitor and the surfactant, and carrying out constant volume filtration. According to the invention, a renewable bio-based material is taken as a core, the etching liquid is weakly acidic to neutral and has low corrosion to equipment, and the waste liquid after use is easy to biodegrade and environment-friendly. Meanwhile, the etching solution has a suitable etching rate and a relatively high etching factor, can obtain a flat etching surface, and can meet the requirements of a copper etching process in the fields of printed circuit boards and the like.

The invention provides a whole blood treatment agent, a kit and application of the whole blood treatment agent in detection of calprotectin, and relates to the technical field of in-vitro detection, the whole blood treatment agent comprises 5-15 mmoL / ml of ammonium chloride or 0.01-0.05 mg / ml of ascorbic acid oxidase, and a solvent is an enzyme diluent. The enzyme diluent is used as a solvent, so that the whole blood treatment agent maintains a stable environment in a sample treatment process, and related enzyme activity is maintained. Ammonium chloride promotes erythrocyte lysis to release hemoglobin; ascorbic acid oxidase can catalyze ascorbic acid to be oxidized into dehydroascorbic acid, and interference factors are reduced. By using the whole blood treatment agent, a tedious pretreatment step on a whole blood sample by using a sample treatment liquid is not needed, the directly collected whole blood sample can be used for subsequent detection after being mixed with the whole blood treatment agent, and the directly collected whole blood sample can be used for subsequent detection, so that the sample treatment is simplified, and the risk of introducing an error due to the sample treatment is reduced; a detection result accords with a clinical diagnosis result, and the accuracy is high.

This invention discloses dehydroascorbic acid-modified hemoglobin-based Paris polyphylla saponin-targeted nanoparticles and their preparation method, belonging to the field of drug delivery system technology. These targeted nanoparticles use hemoglobin as a drug carrier and Paris polyphylla saponin VII as the core active ingredient. The process involves first synthesizing a DSPE-PEG-DHA polymer, then utilizing the property of Hb exposing its hydrophobic region under acidic conditions to encapsulate PSVII within Hb via a self-assembly method, and finally modifying it with DSPE-PEG-DHA to obtain the target nanoparticles PSHb@DPD. This invention significantly enhances the targeting and cellular uptake efficiency of nanoparticles by specifically binding DHA to glucose transporters highly expressed in osteosarcoma cells. It exhibits strong toxicity to osteosarcoma MG63 cells and effectively inhibits their migration, while showing no significant toxicity to normal vascular endothelial cells and excellent biocompatibility.